DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Hurwitz H, Fehrenbacher L, Cartwright T. et al.
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first line therapy in subjects with metastatic CRC.
Proc Am Soc Clin Oncol 2003; 22: 3636-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.